Director Peter A. Thompson of Sionna Therapeutics, Inc. (NASDAQ:SION) completed a series of stock sales that amounted to 510,683 shares and totaled $22,945,043. The transactions unfolded over three consecutive trading days in April 2026 and were carried out under a pre-arranged 10b5-1 trading plan.
The individual transactions were recorded as follows: on April 14, Thompson sold 47,814 shares priced at $44.51 per share; on April 15, he sold 235,863 shares at $44.64 per share; and on April 16, he sold 226,906 shares at $45.34 per share. At the time of reporting, the stock is trading at $45.24, which places it close to its 52-week high of $46.10 and following a 352% increase over the past year.
Despite these dispositions, Thompson retains an indirect stake in Sionna: 3,020,119 shares are held through OrbiMed Private Investments VIII, LP. The use of a pre-established 10b5-1 plan is noted in the filings as the mechanism for these sales.
Recent analyst and financial context
Analyst activity and company disclosures provide additional context to the recent insider sales. Guggenheim has raised its price target on Sionna Therapeutics from $45 to $50 while maintaining a Buy rating. Separately, Citizens initiated coverage on the company with a Market Outperform rating and set a price target of $63; the Citizens valuation was derived using a risk-adjusted, discounted cash flow model by analyst Jonathan Wolleben.
Sionna closed fiscal year 2025 with $310.3 million in cash on hand and has projected that its cash runway extends until 2028. Operationally, the company is progressing its Phase IIa preciSION study, which aims to produce a material improvement in patients with cystic fibrosis.
What the filings show
The SEC filings disclose the precise share counts, per-share prices, and total consideration for the three transactions executed from April 14 to April 16, 2026. They also document Thompson's ongoing indirect ownership through OrbiMed Private Investments VIII, LP and confirm the trades were made under a 10b5-1 arrangement.
This combination of insider sales, analyst target adjustments, reported cash position, and an active late-stage clinical program forms the factual backdrop to Sionna's current market profile. No additional claims or interpretations beyond the disclosed figures and analyst notes are made here.